Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2010-022315-19 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study has the aim to evaluate the improvement in CNS symptoms measured by International Co-operative Ataxia Rating Scale (ICARS) in patients with ataxia teleangectasia (AT), during a period of treatment with ERY-DEX (dexamethasone sodium phosphate ex vivo encapsulated into human autologous erythrocytes).
This is a multi-centre, single arm, open label, 6 months, phase II study to evaluate the effect of ERY-DEX in improving Central Nervous System (CNS) symptoms in patients with Ataxia Teleangectasia (AT). The study consists of a screening period (max duration of 30 days) and a treatment period (duration 6 months).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ERY-DEX | Experimental | Patients treated with monthly treatment of ERY-DEX (dexamethasone sodium phosphate encapsulated in autologous erythrocytes) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dexamethasone | Drug | Dexamethasone sodium phosphate (2 vials, 250 mg/10 ml each) to be administered via encapsulation into autologous erythrocytes (ERY-DEX system). Final amount administered to the patient: about 10-15 mg of dexamethasone sodium phosphate, encapsulated into autologous blood (2 vials of 250 mg each of dexamethasone sodium phosphate will be used in the ex vivo process together with 50 ml of blood previously taken from the same patient). The treatment has to be repeated at intervals of 30 days (±10 days) |
| Measure | Description | Time Frame |
|---|---|---|
| Mean Change From Baseline in Neurological Symptoms Assessed by Using International Cooperative Ataxia Rating Scale (ICARS) Score - ITT Population | ICARS ia a 100-point semiquantitative scale, which goes from 0 to 100, offering a compartimentalised quantification of 4 subscores: Posture and Gait Disturbances (maximum score = 34), Kinetic Functions (maximum score = 52), Speech Disorders (maximum score = 8), and Oculomotor Disorders (maximum score = 6) for a possible total score of 100 points. The minimum score is 0 (normal), while the maximum score is 100 and corresponds to the worst status of the patient. This means that for each subscale, higher scores indicate higher levels of impairment. | At visits 2 (day 30), 4 (day 90) and 7 (final visit, day 180) |
| Mean Change From Baseline in Neurological Symptoms Assessed by Using International Cooperative Ataxia Rating Scale (ICARS) Score - PP Population | ICARS ia a 100-point semiquantitative scale, which goes from 0 to 100, offering a compartimentalised quantification of 4 subscores: Posture and Gait Disturbances (maximum score = 34), Kinetic Functions (maximum score = 52), Speech Disorders (maximum score = 8), and Oculomotor Disorders (maximum score = 6) for a possible total score of 100 points. The minimum score is 0 (normal), while the maximum score is 100 and corresponds to the worst status of the patient. This means that for each subscale, higher scores indicate higher levels of impairment. | At visits 2 (day 30), 4 (day 90) and 7 (final visit, day 180) |
| Measure | Description | Time Frame |
|---|---|---|
| Change From V4 to V7 in Investigator Global Assessment (IGA) - ITT Population | An evaluation of the global health status of the patients by the IGA was performed. IGA consisted of an evaluation of neurological signs and symptoms as neuromotor disorders, posture and deambulation, disturbances of the oro-pharyngeal apparatus, presence of peripheral neuropathy, neurodevelopmental disturbances, intellectual level, and behavior disturbances based only on a subjective judgment of the Investigator on a single scale: a 5-point qualitative scale as:
|
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Luciana Chessa, MD | A.O. Sant'Andrea Rome Italy | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Spedali Civili | Brescia | 25123 | Italy | |||
| University La Sapienza |
Not provided
Not provided
Not provided
Not provided
Not provided
Patients had 30 days of wash-out from steroid assumption before starting the treatment. 26 patients were screened, 4 of them resulted screening failure, due to lymphocytes value below the limit (3) and concomitant disease (1).
Study was carried out in 2 Italian Hospitals. Recruitment started on February 2011 and LPLV was performed on August 2011.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | EryDex | Patients treated with monthly treatment of EryDex (dexamethasone sodium phosphate encapsulated in autologous erythrocytes). |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
The study enrolled 22 patients, 11 male and 11 female with a mean age of 11.2. All the enrolled patients received a monthly treatment of EryDex for 6 consecutive months.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | ERY-DEX | Patients treated with monthly treatment of ERY-DEX (dexamethasone sodium phosphate encapsulated in autologous erythrocytes) |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Mean Change From Baseline in Neurological Symptoms Assessed by Using International Cooperative Ataxia Rating Scale (ICARS) Score - ITT Population | ICARS ia a 100-point semiquantitative scale, which goes from 0 to 100, offering a compartimentalised quantification of 4 subscores: Posture and Gait Disturbances (maximum score = 34), Kinetic Functions (maximum score = 52), Speech Disorders (maximum score = 8), and Oculomotor Disorders (maximum score = 6) for a possible total score of 100 points. The minimum score is 0 (normal), while the maximum score is 100 and corresponds to the worst status of the patient. This means that for each subscale, higher scores indicate higher levels of impairment. | Intent to treat population (ITT) patients receiving at least one treatment | Posted | Mean | Standard Deviation | units on a scale | At visits 2 (day 30), 4 (day 90) and 7 (final visit, day 180) |
|
The adverse events were monitored and collected during the 6 month study period
Please note that non serious Adverse Events were monitored/assessed without regard to the specific Adverse Event Term but only by SOC.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Ery-Dex | Patients treated with monthly treatment of Ery-Dex (dexamethasone sodium phosphate encapsulated in autologous erythrocytes) |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Bronchopneumonia | Infections and infestations | MedDRA (10.0) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| General disorders | General disorders | MedDRA (10.0) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Clinical Study Coordinator | EryDel spa | +39 02 36504470 | guenter.janhofer@erydel.com |
Not provided
| ID | Term |
|---|---|
| D009422 | Nervous System Diseases |
| D030342 | Genetic Diseases, Inborn |
| ID | Term |
|---|---|
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Not provided
Not provided
| ID | Term |
|---|---|
| D003907 | Dexamethasone |
| C004180 | dexamethasone 21-phosphate |
| ID | Term |
|---|---|
| D011246 | Pregnadienetriols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| At visit 7 (final visit, day 180) |
| Change From V4 to V7 in Investigator Global Assessment (IGA) - PP Population | An evaluation of the global health status of the patients by the IGA was performed. IGA consisted of an evaluation of neurological signs and symptoms as neuromotor disorders, posture and deambulation, disturbances of the oro-pharyngeal apparatus, presence of peripheral neuropathy, neurodevelopmental disturbances, intellectual level, and behavior disturbances based only on a subjective judgment of the Investigator on a single scale: a 5-point qualitative scale as:
| At visit 7 (final visit, day 180) |
| Mean Change From V4 to V7 in Ocular Motility - ITT Population | An evaluation of ocular motility measured by an ad hoc form was performed at V4 and V7. At V4 and V7, ocular motility was assessed through a 5-point qualitative scale: very much improved (1), slightly improved (2), no change (3), slightly worsened (4), very much worsened (5). | At visit 7 (final visit, day 180) |
| Mean Change From V4 to V7 in Ocular Motility - PP Population | An evaluation of ocular motility measured by an ad hoc form was performed at V4 and V7. At V4 and V7, ocular motility was assessed through a 5-point qualitative scale: very much improved (1), slightly improved (2), no change (3), slightly worsened (4), very much worsened (5). | At visit 7 (final visit, day 180) |
| Change From Baseline for Vineland Adaptive Behaviour Scale (VABS) Total Score - ITT Population | VABS aggregate scale is used. VABS is divided into 4 adaptive domains and 11 subdomains:
For each *question* in each of the 11 subdomains, score ranges from 0 to 4 (the higher the value the better the outcome):
Domains min-max interval scores: 0-74 Communication, 0-74 Daily Living Skills, 0-62 Socialization, 0-111 Motor Skills, Sum-of-domains score 0-321(the higher the score, the better the outcome) | At visits 4 (90 days) and 7 (180 days, final visit) |
| Change From Baseline for Vineland Adaptive Behaviour Scale (VABS) Total Score - PP Population | VABS aggregate scale is used. VABS is divided into 4 adaptive domains and 11 subdomains:
For each *question* in each of the 11 subdomains, score ranges from 0 to 4 (the higher the value the better the outcome):
Domains min-max interval scores: 0-74 Communication, 0-74 Daily Living Skills, 0-62 Socialization, 0-111 Motor Skills, Sum-of-domains score 0-321(the higher the score, the better the outcome) | At visits 4 (90 days) and 7 (180 days, final visit) |
| Count of Participants on ERY-DEX Showing Treatment Emergent Adverse Events (TEAEs) Including Serious Adverse Events (SAEs) | The effect of ERY-DEX on treatment emergent adverse events was expressed as the number of patients showing at least one TEAE or 1 serious AE | Throughout the study, until the end of 6 months of treatment (day 180) |
| Rome |
| 00185 |
| Italy |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
Patients treated with monthly treatment of ERY-DEX (dexamethasone sodium phosphate encapsulated in autologous erythrocytes)
Dexamethasone sodium phosphate (2 vials, 250 mg/10 ml each) to be administered via encapsulation into autologous erythrocytes (ERY-DEX system). Final amount administered to the patient: about 10-15 mg of dexamethasone sodium phosphate, encapsulated into autologous blood (2 vials of 250 mg each of dexamethasone sodium phosphate will be used in the ex vivo process together with 50 ml of blood previously taken from the same patient).
The treatment has to be repeated at intervals of 30 days (±10 days)
|
|
|
| Primary | Mean Change From Baseline in Neurological Symptoms Assessed by Using International Cooperative Ataxia Rating Scale (ICARS) Score - PP Population | ICARS ia a 100-point semiquantitative scale, which goes from 0 to 100, offering a compartimentalised quantification of 4 subscores: Posture and Gait Disturbances (maximum score = 34), Kinetic Functions (maximum score = 52), Speech Disorders (maximum score = 8), and Oculomotor Disorders (maximum score = 6) for a possible total score of 100 points. The minimum score is 0 (normal), while the maximum score is 100 and corresponds to the worst status of the patient. This means that for each subscale, higher scores indicate higher levels of impairment. | The PP Population includes 18 patients who have been treated according to protocol and fulfill the following criteria:
| Posted | Mean | Standard Deviation | units on a scale | At visits 2 (day 30), 4 (day 90) and 7 (final visit, day 180) |
|
|
|
|
| Secondary | Change From V4 to V7 in Investigator Global Assessment (IGA) - ITT Population | An evaluation of the global health status of the patients by the IGA was performed. IGA consisted of an evaluation of neurological signs and symptoms as neuromotor disorders, posture and deambulation, disturbances of the oro-pharyngeal apparatus, presence of peripheral neuropathy, neurodevelopmental disturbances, intellectual level, and behavior disturbances based only on a subjective judgment of the Investigator on a single scale: a 5-point qualitative scale as:
| The ITT Population includes all 22 patients enrolled into the study. | Posted | Mean | Standard Deviation | units on a scale | At visit 7 (final visit, day 180) |
|
|
|
| Secondary | Change From V4 to V7 in Investigator Global Assessment (IGA) - PP Population | An evaluation of the global health status of the patients by the IGA was performed. IGA consisted of an evaluation of neurological signs and symptoms as neuromotor disorders, posture and deambulation, disturbances of the oro-pharyngeal apparatus, presence of peripheral neuropathy, neurodevelopmental disturbances, intellectual level, and behavior disturbances based only on a subjective judgment of the Investigator on a single scale: a 5-point qualitative scale as:
| The PP Population includes 18 patients who have been treated according to protocol and fulfill the following criteria:
| Posted | Mean | Standard Deviation | units on a scale | At visit 7 (final visit, day 180) |
|
|
|
| Secondary | Mean Change From V4 to V7 in Ocular Motility - ITT Population | An evaluation of ocular motility measured by an ad hoc form was performed at V4 and V7. At V4 and V7, ocular motility was assessed through a 5-point qualitative scale: very much improved (1), slightly improved (2), no change (3), slightly worsened (4), very much worsened (5). | The ITT Population includes all 22 patients enrolled into the study. | Posted | Mean | Standard Deviation | units on a scale | At visit 7 (final visit, day 180) |
|
|
|
| Secondary | Mean Change From V4 to V7 in Ocular Motility - PP Population | An evaluation of ocular motility measured by an ad hoc form was performed at V4 and V7. At V4 and V7, ocular motility was assessed through a 5-point qualitative scale: very much improved (1), slightly improved (2), no change (3), slightly worsened (4), very much worsened (5). | The PP Population includes 18 patients who have been treated according to protocol and fulfill the following criteria:
| Posted | Mean | Standard Deviation | units on a scale | At visit 7 (final visit, day 180) |
|
|
|
| Secondary | Change From Baseline for Vineland Adaptive Behaviour Scale (VABS) Total Score - ITT Population | VABS aggregate scale is used. VABS is divided into 4 adaptive domains and 11 subdomains:
For each *question* in each of the 11 subdomains, score ranges from 0 to 4 (the higher the value the better the outcome):
Domains min-max interval scores: 0-74 Communication, 0-74 Daily Living Skills, 0-62 Socialization, 0-111 Motor Skills, Sum-of-domains score 0-321(the higher the score, the better the outcome) | The ITT Population includes all 22 patients enrolled into the study. | Posted | Mean | Standard Deviation | units on a scale | At visits 4 (90 days) and 7 (180 days, final visit) |
|
|
|
|
| Secondary | Change From Baseline for Vineland Adaptive Behaviour Scale (VABS) Total Score - PP Population | VABS aggregate scale is used. VABS is divided into 4 adaptive domains and 11 subdomains:
For each *question* in each of the 11 subdomains, score ranges from 0 to 4 (the higher the value the better the outcome):
Domains min-max interval scores: 0-74 Communication, 0-74 Daily Living Skills, 0-62 Socialization, 0-111 Motor Skills, Sum-of-domains score 0-321(the higher the score, the better the outcome) | The PP Population includes 18 patients who have been treated according to protocol and fulfill the following criteria:
| Posted | Mean | Standard Deviation | units on a scale | At visits 4 (90 days) and 7 (180 days, final visit) |
|
|
|
|
| Secondary | Count of Participants on ERY-DEX Showing Treatment Emergent Adverse Events (TEAEs) Including Serious Adverse Events (SAEs) | The effect of ERY-DEX on treatment emergent adverse events was expressed as the number of patients showing at least one TEAE or 1 serious AE | The SP includes the 22 patients who have received at least one dose of planned trial treatment. | Posted | Count of Participants | Participants | Throughout the study, until the end of 6 months of treatment (day 180) |
|
|
|
| 0 |
| 22 |
| 2 |
| 22 |
| 15 |
| 22 |
| Bronchiectasis | Respiratory, thoracic and mediastinal disorders | MedDRA (10.0) | Systematic Assessment |
|
| immune disorders | Immune system disorders | MedDRA (10.0) | Systematic Assessment |
|
| infections and infestations | Infections and infestations | MedDRA (10.0) | Systematic Assessment |
|
| respiratory disorders | Respiratory, thoracic and mediastinal disorders | MedDRA (10.0) | Systematic Assessment |
|
Not provided
| D000072473 |
| Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D013259 | Steroids, Fluorinated |
| Title | Measurements |
|---|---|
|